Equities

InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2354
  • Today's Change-0.019 / -7.29%
  • Shares traded641.14k
  • 1 Year change-82.17%
  • Beta0.6027
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

  • Revenue in USD (TTM)5.63m
  • Net income in USD-6.08m
  • Incorporated1981
  • Employees13.00
  • Location
    InMed Pharmaceuticals IncSUITE 310, 815 W. HASTINGS STREETVANCOUVER V6C 1B4CanadaCAN
  • Phone+1 (604) 669-7207
  • Fax+1 (778) 945-6800
  • Websitehttps://www.inmedpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Finch Therapeutics Group Inc0.00-16.28m2.30m18.00--0.1209-----10.14-10.140.0011.860.00-------25.22---28.97--------------0.00---87.57--34.80------
Axim Biotechnologies Inc85.35k-5.59m2.31m6.00------27.05-0.0249-0.02490.0003-0.02680.0214----14,225.00-140.13-154.34---390.73-----6,548.75-36,362.71---1.16----345.05-27.38-29.10------
Eloxx Pharmaceuticals Inc0.00-20.48m2.31m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Aclarion Inc60.05k-6.13m2.41m6.00--0.838--40.10-7.41-7.410.03410.35020.0215--3.5010,008.33-219.26---337.53---29.49---10,203.20------0.211--24.75--34.38------
Veritas Farms Inc730.65k-6.15m2.46m17.00--12.14--3.36-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
Agile Therapeutics Inc21.50m-7.79m2.49m19.00------0.1156-3.65-3.656.98-1.511.632.905.421,131,316.00-59.25-94.24---142.6259.73---36.26-513.500.3843------80.02--43.08------
PaxMedica Inc0.00-18.15m2.50m6.00--2.01-----11.19-11.190.000.15940.00----0.00-474.77-755.77-781.78-------------3,015.030.00-------23.56------
InMed Pharmaceuticals Inc5.63m-6.08m2.51m13.00--0.1717--0.4464-1.23-1.230.92841.750.40062.7129.77---43.26-88.10-50.03-104.1939.20---108.01-1,066.115.80--0.00--279.60--57.27--29.56--
Virax Biolabs Group Ltd0.00-1.71m2.53m5.00---------1.50-1.500.00-0.8568------0.00----------------0.0223-112.29-----100.00---162.50------
Qrons Inc0.00-763.52k2.53m2.00---------0.0562-0.05620.00-0.10780.00----0.00-18,782.78-1,513.45---------------19.02---------7.61------
cbdMD Inc21.58m-25.65m2.55m52.00--0.6522--0.1183-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
CYANOTECH CORP22.49m-4.62m2.60m86.00--0.1867--0.1157-0.7265-0.72653.532.010.78891.5310.73261,546.50-16.19-2.32-21.07-2.9629.5935.88-20.52-2.330.3702-5.930.3299---35.56-7.44-259.70--1.22--
Sentient Brands Holdings Inc0.00-818.63k2.65m2.00---------0.0145-0.01450.00-0.0360.000.0188--0.00-317.87-220.36------41.81---31,451.190.0354-2.27-----73.68--34.98------
AgriFORCE Growing Systems Ltd16.28k-13.34m2.74m7.00--0.2654--168.09-10.78-10.780.00390.3960.0009--0.4432,325.71-74.39-78.95-100.77-109.8616.58---81,946.25-243,182.500.8186-1.300.1913------8.85--48.61--
Novelstem International Corp15.00k-4.22m2.82m15.00------187.84-0.09-0.090.0003-0.04780.0065--10.00---172.16---1,011.77-------26,418.53-----8.402.34--0.00---446.84------
Data as of Jun 07 2024. Currency figures normalised to InMed Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

11.32%Per cent of shares held by top holders
HolderShares% Held
Sabby Management LLCas of 31 Mar 2024361.73k5.97%
Armistice Capital LLCas of 31 Mar 2024266.97k4.41%
Renaissance Technologies LLCas of 31 Mar 202428.30k0.47%
Two Sigma Securities LLCas of 31 Mar 202415.42k0.26%
Citadel Securities LLCas of 31 Mar 202412.73k0.21%
Qube Research & Technologies Ltd.as of 31 Mar 2024200.000.00%
BFSG LLCas of 31 Mar 2024200.000.00%
BofA Securities, Inc.as of 31 Mar 2024100.000.00%
AdvisorNet Financial, Inc.as of 31 Mar 202480.000.00%
UBS Securities LLCas of 31 Mar 202441.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.